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B cells, by virtue of their diverse roles in immune responses 
to foreign and self antigens, have become of increasing inter-
est to the clinician as well as the basic immunologist. In par-
ticular, it is now apparent that the development of B cell un-
responsiveness in antibody and T cell mediated autoimmune 
disorders and the transplant setting is both worthwhile and 
achievable. [Immune Network 2010;10(3):81-84]
INTRODUCTION
The development of the B cell repertoire in humans and ro-
dents occurs in two stages: during the first VDJ gene recombi-
nation  within  primary  lymphoid  tissue  (eg  bone  marrow 
(BM)) leads to expression of specific antigen receptors (BCRs) 
on immature B cells which can then recognise their cognate 
antigens as they undergo further differentiation in peripheral 
lymphoid tissue. The second stage takes place largely within 
germinal centres (GCs) where B cells undergoing somatic hy-
permutation are positively selected for increasing affinity, but 
negatively selected against self (1). Due to the random nature 
of these processes self-reactive B cells are generated as well 
as B cells with useful anti-foreign specificities. Consequently 
there is a need for regulatory mechanisms to operate at multi-
ple checkpoints throughout B cell differentiation in the BM 
and  peripheral  lymphoid  tissue  (2-4).
SPECTRUM OF B CELL FUNCTIONS
It has become apparent in the past 5 years that B cells, like 
T cells have a broad range of functional capabilities. Not only 
do they produce antibodies, but they can transfer antigen in 
peripheral lymphoid tissue (5), act as antigen presenting cells 
(APC) and secrete pro- and anti-inflammatory cytokines and 
chemokines. Thus, depending on the circumstances they be-
have as either effector or regulatory cells (6-8). Moreover, it 
appears that in both mouse (9) and man (10) there is a dis-
crete subset of IL-10 secreting B cells with regulatory proper-
ties (Bregs) which can switch off T as well as B cell mediated 
immune responses. The indirect effects of B cell dependent 
suppression on the T cell compartment include deletion, in-
duction of anergy and selective expansion of Tregs (9). This 
range of presentation-related functions is now being exploited 
to treat a variety of immunopathic conditions involving both 
T  cells  and  antibodies.  For  example,  Bregs  are  being  en-
gineered  by  transfecting  naïve  B  cells  with  the  antigen  in 
question (eg self antigens like factor  VIII in models of hae-
mophilia where allo-antibodies have been generated) coupled 
to  an  IgG  heavy  chain  scaffold  (11). 
ROLE OF B CELLS IN AUTOIMMUNE DISEASE
Pathogenesis
The precise role of B cells in pathogenesis of autoimmune 
d i s e a s e s  h a s  b e e n  s t u d i e d  i n  t w o  m a i n  w a y s .  T h e  f i r s t  i n -
volves crossing autoimmune prone mice with B cell deficient 
(eg muMT or anti-CD20 antibody treated) mice and determin-
ing whether disease still occurs or not. For example, type-1 
diabetes prone NOD mice lacking B cells fail to develop clin-
ical disease due to a failure in activation of self-reactive effec-The Role of B Cells in Transplantation and Immunopathic Diseases
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tor T cells (12). Likewise Aire deficient mice the organs of 
which are heavily infiltrated with B cells lose their suscepti-
bility to multiple autoimmune disorders when bred on to a 
B cell deficient background or after being  treated with an-
t i - C D 2 0  a n t i b o d y  ( 1 3 ) .  I n  t h i s  m o d e l  a s  w e l l  a s  t h e  N O D  
m o u s e ,  B  c e l l s  e x e r t  t h e i r  p a t h o g e n i c  e f f e c t  t h r o u g h  p r e -
sentation  of  self-antigen  and  possibly  release  of  proin-
flammatory cytokines. The second approach involves study-
ing human neonates for development of autoimmunity. Since 
the great majority of autoantibodies belong to the IgG class 
and  therefore can  cross  the placenta, development of tran-
sient autoimmune disease post-natally is a neat way of prov-
ing that autoantibodies per se and not other B cell activities 
are responsible. Examples include Graves disease, myasthe-
nia gravis, ITP, certain bullous skin diseases and Lupus asso-
ciated congenital heart block. In some other instances auto-
antibodies even though not directly pathogenic can be val-
uable diagnostic and/or prognostic markers, for instance, islet 
cell antibodies in type 1 diabetes and antibodies to mitochon-
dria or smooth muscle in autoimmune liver disease. By con-
trast the principle role of B cells in diseases like multiple scle-
rosis, rheumatoid arthritis and the chronic inflammatory de-
myelinating neuropathies (in addition to type 1 diabetes (see 
above)) is probably as APCs. Interestingly deposition of auto-
antibody containing immune complexes in tissues is no lon-
ger considered to be a primary event in autoimmune states, 
but  rather  on  of  the  pathogenic  pathways  that  contribute 
downstream to tissue destruction once self-tolerance has been 
broken.
Anti-B cell therapy
Over the past five years B cell depletion particularly with anti- 
CD20 antibodies has become an accepted second line modal-
ity  of  therapy  for  patients  with  refractory  autoimmune  dis-
eases (14). Thus promising results have been obtained with 
anti-CD20 antibodies in patients with seropositive rheumatoid 
arthritis who have failed therapy with the combination of TNF 
inhibitors  and  methotrexate  (15-17).  Less  impressive  re-
sponses have been obtained in patients with moderate to se-
vere lupus (18), although some promise has been shown in 
relapsing remitting multiple sclerosis (19). What is of clinical 
importance, however, is that depletion of circulating B cells 
is not associated with an increased incidence of serious in-
fection, presumably due to the sparing of long-lived anti-for-
eign plasma cells in the bone marrow (20,21). Inhibition of 
BAFF with a BCMA fusion protein was shown to be effica-
cious in preventing the onset of Type 1 diabetes in the NOD 
model, this effect being due not only to B cell depletion, but 
to alterations in effector and regulatory T cell subsets (22). 
Moreover, the use of anti-CD20 in patients with recent onset 
TID  appeared  to  be  associated  with  lower  insulin  require-
ments and higher C peptide levels (23). Due to their wide-
spread applications, B cell depletion techniques are shedding 
significant light on the positive and negative functions of ma-
ture  B  cell  subsets  (24).
ROLE OF B CELLS IN TRANSPLANTATION
B  c e l l s  a s  o p p o s e d  t o  T  c e l l s  h a v e  r e c e i v e d  r e l a t i v e l y  l i t t l e 
attention in a transplant setting until recently. Nevertheless it 
comes  as  no  surprise  that  B  cells  are  becoming  of  much 
greater interest in this field given their regulatory as well as 
effector  functions.
Hemopoietic stem cell transplantation
The major residual clinical challenge in allogeneic stem cell 
transplantation  remains  acute  and  chronic  graft  versus  host 
disease (GVHD) and their control while retaining the benefi-
cial effects of the graft versus leukemia effect. In acute GVHD 
there is minimal evidence of a role for B cells; consequently 
B cell depletion with anti-CD20 antibodies is ineffective ex-
cept if given pre-transplant when it may cause a slight reduc-
tion in cumulative incidence of rejections (25). By contrast, 
B cells have clearly been shown to be important in chronic 
GVHD (25). Thus this syndrome is characterised by high cir-
culating levels of BAFF and development of associated auto-
antibody mediated autoimmune diseases (eg ITP and glomer-
ulonephritis).  Moreover  there  is  a  correlation  between  an-
ti-HY antibodies and chronic GVHD. Predictably therefore B 
cell  depletion  with  anti-CD20  antibody  is  beneficial  (25). 
Interestingly infusion of pooled intravenous immunoglobulin 
given pre- or post transplantation does not ameliorate either 
acute or chronic GVHD despite its potent anti-inflammatory 
activity, whereas it remains an accepted form of therapy in 
solid  organ  (eg  renal)  transplants  (26). 
Solid organ transplantation
The  role  of  B  cells  in  hyperacute  graft  rejection i s  w e l l  
established. In the case of xenografts, hyperacute rejection is 
mediated by ‘natural’ anti- glycolipid antibodies derived from 
B1 cells, while pre-existing antibodies to ABO blood group 
antigens or HLA are responsible for the same process in allog-The Role of B Cells in Transplantation and Immunopathic Diseases
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raft recipients (27). The only clinical situation where human 
allografts  (eg  cardiac)  have  been  successfully  transplanted 
across an ABO or full HLA mismatch is in the neonatal period 
where it is possible to capitalise on the relative immaturity 
of the infant’s immune system (28). Success in humans with 
xenografts remains an important challenge given the chronic 
shortage of human organ donors. It is therefore encouraging 
t h a t  p r o m i s i n g  r e s u l t s  a r e  b e i n g  o b t a i n e d  i n  e x p e r i m e n t a l  
models involving creation of mixed xenogeneic bone marrow 
chimeras (29). These models depend on ablating the recipi-
ent’s immune system before transplantation in order to capi-
talise on the sensitivity of immature B cells to tolerance in-
duction  during  reconstitution  with  BM  precursors.   
    With respect to acute allograft rejection, conventional dog-
ma has it that T cells are the primary effectors. However, two 
lines  of  evidence  have  emerged  that  point  to  a  role  for  B 
cells as well. First, significant numbers of B cells and plasma 
cells have been demonstrated in the cellular infiltrate of re-
jecting renal allografts (30). Secondly and based on these data 
anti-CD20 antibody, when added to anti -T cell and cytotoxic 
drug  therapy,  has  been  shown  to  reduce  the  rejection  rate 
of human renal allografts (31) and primate islet cell grafts in 
an  experimental  model  (32). 
  As was the case with certain types of autoimmune disease 
(see above), the primary contribution of B cells to allograft 
responses, other than hyperacute rejection is likely to be due 
to their role in antigen presentation to T cells. Support for 
this contention comes from the demonstration by Terasaki’s 
group that antibodies to HLA and non-HLA antigens are pre-
dictive of renal allograft rejection in only about 50% of cases 
(33).  On  the  other  hand,  the  proportion  of  B  lineage  cells 
in grafts does not appear to be a reliable indicator of graft 
survival versus loss (30,34). Interestingly the same conclusion 
has been reached concerning infiltrating Tregs (34) which is 
in  striking  contrast  to  their  well  established  prognostic  role 
in  human  tumours  (35-37).
CONCLUSIONS
B cells in addition to producing antibodies secrete pro- and 
anti- inflammatory cytokines and chemokines, transport anti-
gens  and  present  them  to  T  cells.  Their  capacity  to  act  as 
regulatory  as  well  as  effector  cells  under  both  normal  and 
pathological conditions means that their role in autoimmunity 
and transplantation has become not only more complex, but 
now offers intriguing new opportunities for therapy using B 
cell  depletion  or  tolerance  induction  in  the  B  cell  com-
partment.
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